Ask Warren

Dongsung Pharmaceutical

002210 · KOSPI · ₩002210 · 동성제약

₩1,196▼ ₩27 (2.21%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩22B₩19B₩19B₩22B₩20B₩26B₩23B₩21B
Cost of sales₩14B₩10B₩12B₩12B₩13B₩14B₩13B₩12B
Gross profit₩8.3B₩9.1B₩7.2B₩10B₩7.4B₩13B₩9.3B₩9.7B
Operating income−₩2B₩289M−₩7.1B₩411M−₩4.2B₩743M−₩3.1B−₩698M
Net income−₩5.9B₩14M−₩26B₩19B−₩17B−₩1.3B−₩13B−₩401M
Net income to shareholders−₩5.9B₩14M−₩26B₩19B−₩17B−₩1.3B−₩13B−₩401M

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩160B₩288B₩168B₩146B₩148B₩169B₩141B₩122B
Current assets₩81B₩209B₩89B₩58B₩60B₩80B₩57B₩69B
Cash and equivalents₩37B₩164B₩3.9B₩4.1B₩5.6B₩7.7B₩3.1B₩704M
Total liabilities₩72B₩195B₩145B₩105B₩107B₩113B₩97B₩85B
Current liabilities₩65B₩179B₩130B₩87B₩90B₩93B₩77B₩71B
Borrowings₩39B₩64B₩64B₩64B₩64B₩65B₩52B₩53B
Total equity₩87B₩93B₩23B₩41B₩41B₩56B₩44B₩37B
Shareholders' equity₩87B₩93B₩23B₩41B₩41B₩56B₩44B₩37B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩20B−₩139M−₩3.3B−₩2.3B₩4.2B−₩11B₩6.3B−₩2.1B
Free cash flow−₩20B−₩139M−₩3.3B−₩2.3B₩4.2B−₩11B₩6.3B−₩2.1B

Consolidated where available. Amounts in won.

Also known as: Dongsung Pharmaceutical / 동성제약 / 002210 / KRX:002210

Source: KRX statistical information